Raymond James & Associates Oric Pharmaceuticals, Inc. Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$17.37 - $25.34 $292,093 - $426,117	-16,816 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$23.67 - $36.85 $237,291 - $369,421	-10,025 Reduced 37.35%	16,816 $412,000
Q4 2020 Feb 12, 2021	SELL	$20.32 - $39.8 $190,703 - $373,523	-9,385 Reduced 25.91%	26,841 $909,000
Q3 2020 Nov 04, 2020	BUY	$19.5 - $31.26 $115,849 - $185,715	5,941 Added 19.62%	36,226 $906,000
Q2 2020 Jul 28, 2020	BUY	$25.68 - $38.12 $777,718 - $1.15 Million	30,285 New	30,285 $1.02 Million

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $336M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.